Alpha Tau's Alpha DaRT Achieves 100% Local Disease Control in Early Pancreatic Cancer Trials
DRTS has more than doubled off its 52-week low of $2.57.
Summary
Alpha Tau Medical reported highly encouraging early clinical data for its Alpha DaRT therapy in pancreatic cancer, demonstrating a 100% local disease control rate across 19 evaluable patients in two first-in-human trials. The results, presented at Digestive Disease Week (DDW) 2026, showed 21% of patients experienced tumor shrinkage and 79% had stable disease, with an encouraging safety profile even in heavily pretreated patients. This is a significant development for a company of Alpha Tau's size, especially given the aggressive nature and poor prognosis of pancreatic cancer. The positive data, which marks the first oral presentation for Alpha DaRT at a major GI meeting, substantially de-risks the program and could drive significant investor interest. Investors should watch for the upcoming combined results from three pancreatic cancer studies at the ASCO Annual Meeting later this month, as well as progress in the U.S. IMPACT trial and other regulatory advancements.
At the time of this announcement, DRTS was trading at $7.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $641.5M. The 52-week trading range was $2.57 to $9.07. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: FinanceWire.